Abbott Laboratories (ABL)
Deutsche Börse Xetra · Germany · prices in EUR · close of 27 Oct 2026
Key indicators
| Last close | EUR 92.68 |
|---|---|
| 52-week range | 70.10 – 113.36 |
| Return, 1 month / 3 months | +4.7% / +0.4% |
| Return, 1 year / 3 years | −12.3% / +12.3% |
| Trend | Uptrend |
| RSI (14) | 56 |
| Volatility (1 year) | 27.5% |
| Worst drawdown (1 year) | -37.2% |
| Average daily value traded | 0.07M EUR |
| Dividend yield | 2.2% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Abbott Laboratories is a healthcare company that develops and makes medical devices, diagnostic tests, nutritional products and branded generic medicines. Its customers include hospitals, laboratories, clinics and consumers who use its nutrition and personal health products. The company is based in Abbott Park, Illinois, in the United States, and it serves healthcare markets around the world through its several operating divisions.
On this site Abbott Laboratories appears as a stock on the Deutsche Börse Xetra (Germany), code ABL, with prices in euros (EUR). Our dividend records, which start in 2019, show payments in 7 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Abbott Laboratories (ABL) trades on the Deutsche Börse Xetra in Germany. It last closed at EUR 92.68 on 27 October 2026.
Its price-based Market X-Ray is 55 out of 100 (a fair price profile), ranking 328 of 701 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 12.3% and over the last three months it rose 0.4%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Deutsche Börse Xetra
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 65 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 6.7% | ||
| From 52-week high | -18.0% | ||
| Momentum | 57 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 0.4% | ||
| 6-month return | 18.3% | ||
| 12-month return, skipping the last month | -16.2% | ||
| Stability (higher is calmer) | 55 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 27.5% | ||
| Worst drawdown, 1 year (smaller is calmer) | -37.2% | ||
| Liquidity | 40 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.07M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 47 · Weak | Dividend is small or irregular. | |
| Dividend yield | 2.2% | ||
| Years with dividends | 5 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Liquidity: Thinly traded: prices can jump and exits can be hard.
- Income: Dividend is small or irregular.
Returns
| 1 week | +0.9% |
|---|---|
| 1 month | +4.7% |
| 3 months | +0.4% |
| 6 months | +18.3% |
| 1 year | −12.3% |
| 3 years | +12.3% |
| 5 years | −7.0% |
Signals
| 50-day / 200-day average | 91.28 / 86.83 |
|---|---|
| Golden / death cross (60 days) | Golden, 38 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 2.09 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 15 Oct 2026 | USD 0.5604 |
| 15 Jul 2026 | USD 0.5604 |
| 15 Apr 2026 | USD 0.5604 |
| 15 Jan 2026 | USD 0.5604 |
| 15 Oct 2025 | USD 0.5248 |
| 15 Jul 2025 | USD 0.5248 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Deutsche Börse Xetra; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.